U.S. Stock Market Performance: U.S. stocks rose on Monday, with the Dow Jones increasing by approximately 250 points, driven by significant gains in various companies.
Alibaba's App Success: Alibaba Group's shares surged 4.7% after the company announced its new AI assistant app, Qianwen, reached 10 million downloads within a week of its launch in China.
Notable Stock Gains: Several companies saw substantial stock increases, including Inspire Medical Systems (up 28.6%), Oscar Health (up 23.3%), and Ondas Holdings (up 20.2%), among others.
Analyst Upgrades and Market Reactions: Stocks like Cipher Mining and Lumentum Holdings experienced gains following analyst upgrades, reflecting positive market sentiment and investor interest in tech and healthcare sectors.
Wall Street analysts forecast BLTE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 167.50 USD with a low forecast of 85.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast BLTE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 167.50 USD with a low forecast of 85.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 153.680
Low
85.00
Averages
167.50
High
200.00
Current: 153.680
Low
85.00
Averages
167.50
High
200.00
Morgan Stanley
Overweight
initiated
$191
Al Analysis
2026-01-06
Reason
Morgan Stanley
Price Target
$191
Al Analysis
2026-01-06
initiated
Overweight
Reason
Morgan Stanley initiated coverage of Belite Bio with an Overweight rating and $191 price target. The firm says its key opinion leader checks support a multi-billion dollar opportunity for tinlarebant in Stargardt disease type 1. Potential regulatory approval and commercial launch are catalysts to move shares higher over the next 12 months, the analyst tells investors in a research note.
Maxim
NULL -> Buy
maintain
$140 -> $200
2025-12-02
Reason
Maxim
Price Target
$140 -> $200
2025-12-02
maintain
NULL -> Buy
Reason
Maxim raised the firm's price target on Belite Bio to $200 from $140 and keeps a Buy rating on the shares after the company reported positive topline results from the Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BLTE
Unlock Now
Mizuho
Graig Suvannavejh
Neutral -> Outperform
upgrade
$194
2025-12-02
Reason
Mizuho
Graig Suvannavejh
Price Target
$194
2025-12-02
upgrade
Neutral -> Outperform
Reason
Mizuho analyst Graig Suvannavejh upgraded Belite Bio to Outperform from Neutral with a $194 price target.
Mizuho
Graig Suvannavejh
Neutral -> Outperform
upgrade
$105 -> $194
2025-12-02
Reason
Mizuho
Graig Suvannavejh
Price Target
$105 -> $194
2025-12-02
upgrade
Neutral -> Outperform
Reason
Mizuho analyst Graig Suvannavejh upgraded Belite Bio to Outperform from Neutral with a price target of $194, up from $105. The firm cites the positive Phase 3 data for tinlarebant in Stargardt disease for the upgrade. The data are "impressive" and better than Mizuho's expectations on both efficacy and safety, the analyst tells investors in a research note. The firm increased its probability of success assumptions for tinlarebant to 85% from 40%-60% prior. Mizuho sees the drug's U.S. launch pricing at $350,000 and moved up its risk-unadjusted tinlarebant sales estimate to $4.2B. It sees further upside in the shares post the data.
About BLTE
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
